Oncogenic JAK2 V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms

• DOI: 10.1126/scitranslmed.aam7729
• Publication Date: 2018-02-21T19:05:25Z
• Authors: Alessandro Presti...; Alica J. Emhardt; Konrad Aumann; David O’Sullivan; Sivahari P. Gorantla; Sandra Duquesne; Wolfgang Melchinger; Lukas Braun; Slavica Vuckovic; Melanie Boerries; Hauke Busch; Sebastian Halbach; Sandra Pennisi; Teresa Poggio; Petya Apostolova; Pia Veratti; Michael Hettich; Gabriele Niedermann; Mark Bartholomä; Khalid Shoumariyeh; Jonas S. Jutzi; Julius Wehrle; Christine Dierks; Heiko Becker; Annette Schmitt-G...; Marie Follo; Dietmar Pfeifer; Jan Rohr; Sebastian Fuchs; Stephan Ehl; Frederike A. Hartl; Susana Minguet; Cornelius Miething; Florian H. Heidel; Nicolaus Kröger; Ioanna Triviai; Tilman Brummer; Jürgen Finke; Anna L. Illert; Eliana Ruggiero; Chiara Bonini; Justus Duyster; Heike L. Pahl; Steven W. Lane; Geoffrey R. Hill; Bruce R. Blazar; Nikolas von Bubnoff; Erika L. Pearce; Robert Zeiser
• Keywords: 0301 basic medicine; Myeloproliferative Disorders; 610; Janus Kinase 2; B7-H1 Antigen; 3. Good health; Mice; 03 medical and health sciences; Cell Transformation, Neoplastic; Hematologic Neoplasms; Tumor Cells, Cultured; Animals; Humans; K562 Cells; Cell Proliferation; Signal Transduction

Oncogenic JAK mutation sensitizes myeloproliferative neoplasms to immune checkpoint inhibition.